Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 16/20 | 0.59 |
| ▸ | F11 | P03951 | 9/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17786820 | 0.92 | KLKB1 (0.53) | KLKB1F11CACNA1H | |
| SCHEMBL17786819 | 0.86 | KLKB1 (0.56) | KLKB1F11F2 | |
| SCHEMBL16246763 | 0.82 | KLKB1 (0.61) | KLKB1F11CACNA1H | |
| SCHEMBL28339182 | 0.82 | KLKB1 (0.59) | KLKB1F11F2CACNA1H | |
| SCHEMBL18725232 | 0.82 | KLKB1 (0.47) | KLKB1F11CACNA1H | |
| SCHEMBL17787030 | 0.81 | KLKB1 (0.46) | KLKB1 | |
| SCHEMBL16246724 | 0.80 | KLKB1 (0.63) | KLKB1F11 | |
| SCHEMBL16246851 | 0.80 | KLKB1 (0.60) | KLKB1 | |
| SCHEMBL31339412 | 0.80 | KLKB1 (0.63) | KLKB1F11 | |
| SCHEMBL18725234 | 0.78 | KLKB1 (0.46) | KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084809-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-08-10 | — | — | US | disclosed |
| US-11001578-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-05-11 | — | — | US | disclosed |
| US-20200361923-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | DRI UK LP (KY) | 2020-11-19 | — | — | US | disclosed |
| US-10611758-B2 | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2020-04-07 | — | — | US | disclosed |
| US-20190330200-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS KALLIKREIN INHIBITORS | DRI UK LP (KY) | 2019-10-31 | — | — | US | disclosed |
| US-20190300517-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | DRI UK LP (KY) | 2019-10-03 | — | — | US | disclosed |
| US-10364238-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20180319782-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | DRI UK LP (KY) | 2018-11-08 | — | — | US | disclosed |
| WO-2016083816-A1 | N-((HETEROARYLMETHYL)-HETEROARYL-CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319782-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885F11 55/4885F2 19/4885 |
| US-10611758-B2 | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885F11 65/4885F2 32/4885 |
| US-10364238-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885F11 55/4885F2 19/4885 |
| US-20190300517-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885F11 65/4885F2 22/4885 |
| US-20200361923-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885F11 65/4885F2 32/4885 |
| US-20190330200-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885F11 65/4885F2 32/4885 |
| US-11001578-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885F11 65/4885F2 22/4885 |
| US-11084809-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885F11 65/4885F2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.